The present invention relates generally to the generation and characterization
of anti-MUC18 monoclonal antibodies. The invention further relates to the use of
such anti-MUC18 antibodies in the diagnosis and treatment of disorders associated
with increased activity of MUC18, in particular, tumors, such as melanomas.
